Pharmalot

Pharmalot By Ed Silverman

FDA tells drug makers to redo studies run by two contract research firms due to data integrity issues

Pharmalot By Ed Silverman

Pharmalittle: Sanofi ends work on mRNA Covid-19 vaccine; Biogen seeks fast FDA approval of another Alzheimer’s drug

Pharmalot By Ed Silverman

Inflation and rebates caused wholesale prices on medicines to drop in second quarter

Pharmalot By Ed Silverman

Pharmalittle: Moderate House Dems’ opposition to drug-pricing reforms shrinks; Glaxo goes on charm offensive

Pharmalot By Ed Silverman

WHO adds Regeneron drug to recommended Covid-19 treatments, but criticizes its pricing

Pharmalot By Ed Silverman

Pharmalittle: CDC director overrules panel and recommends Pfizer shot for at-risk workers; DOD watchdog faults military over pharma supply chain issues

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Defense Department watchdog criticizes oversight of military’s pharmaceutical supply chain

Pharmalot By Ed Silverman

Pharmalittle: Pfizer CEO rallies employees to fight drug-price negotiations; Glaxo head pressured by another activist fund

Pharmalot By Ed Silverman

Federal officials move closer to penalizing drug makers for failing to offer discounts to safety-net hospitals

Pharmalot By Ed Silverman

Compound pharmacies win court battle over an FDA plan for monitoring shipments

Pharmalot By Ed Silverman

Pharmalittle: Biogen considers layoffs amid poor Alzheimer’s drug sales; House Dems plan showdown on drug-pricing vote

Pharmalot By Ed Silverman

Pharmalittle: J&J says its Covid-19 shot is more effective in two doses; India plans to resume Covid-19 vaccine exports

Pharmalot By Ed Silverman

U.S. lawmakers accuse patent office of weakening challenges and allowing drug prices to rise

Pharmalot By Ed Silverman

Citing competitive concerns, European Commission seeks to intervene in Illumina’s $8 billion acquisition of Grail

Pharmalot By Ed Silverman

Pharmalittle: Key Senate panel proposes expanded pharma pricing penalties; Biden will urge Covid-19 summit to help poor nations get vaccines

Pharmalot By Ed Silverman

Former Mylan IT exec pleads guilty to insider trading on earnings, drug approvals, and merger

Pharmalot By Ed Silverman

U.K. government launches a new system to monitor clinical trial reporting

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: FDA advisory panel to decide on Covid-19 boosters; Justice Dept. trustee appeals Purdue bankruptcy deal

Pharmalot By Casey Ross

Pharmalittle: FDA scientists skeptical on boosters; moderate Democrats sink Pelosi’s drug pricing proposal

Pharmalot By Ed Silverman

A ‘wonky’ congressional report will be a pharma talking point in the drug pricing debate

Pharmalot By Ed Silverman

Safety-net hospitals take big markups on cancer drugs for commercially insured patients, study finds

Pharmalot By Ed Silverman

After a court let them off the hook, generic Zantac makers plan to seek legal expenses from consumers

Pharmalot By Ed Silverman

Pharmalittle: Moderate Democrats threaten House drug-pricing bill; FDA reverses decision on reviewing ALS drug

Pharmalot By Ed Silverman

Pharmalittle: Purdue execs get their bonuses; Woodcock, two senators push patent office over pharma abuse

Pharmalot By Ed Silverman

FDA commissioner, two senators raise concerns about patent abuse by pharmaceutical companies

Pharmalot By Ed Silverman

Pharmalittle: International experts argue against Covid-19 boosters; centrist House Dems to release separate drug-pricing proposal

Pharmalot By Ed Silverman

Cancer drug indications remain on labels even after trials fail to confirm their benefits